lansoprazole has been researched along with tenatoprazole in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bakmiwewa, SM; Ball, HJ; Fatokun, AA; Hunt, NH; Payne, RJ; Tran, A | 1 |
| Bi, Y; Kuberan, B; Might, M; Vankayalapati, H | 1 |
| Beghyn, T; Bosc, D; Charton, J; Deprez, B; Deprez-Poulain, R; Guillaume, V; Herledan, A; Hermant, P; Landry, V; Leroux, F; Liang, W; Pottiez, V; Sheng, L; Tang, WJ; Urata, S; Warenghem, S | 1 |
| Araki, T; Kakinoki, B; Morinaka, Y; Takeuchi, Y; Uchiyama, K; Wakatsuki, D | 1 |
| Hofmann, U; Nies, AT; Resch, C; Rius, M; Schaeffeler, E; Schwab, M | 1 |
| Arnaud, B; Arnoult, C; Escoffier, J; Hograindleur, JP; Kaba, M; Le Blévec, E; Martinez, G; Nef, S; Ray, PF; Stévant, I | 1 |
6 other study(ies) available for lansoprazole and tenatoprazole
| Article | Year |
|---|---|
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
Topics: Animals; Dose-Response Relationship, Drug; Enzyme Inhibitors; HEK293 Cells; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Substrate Specificity | 2012 |
Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-β-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease.
Topics: Dose-Response Relationship, Drug; Enzyme Inhibitors; Genetic Diseases, Inborn; Humans; Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase; Molecular Structure; Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Small Molecule Libraries; Structure-Activity Relationship | 2017 |
Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
Topics: Azoles; Biocatalysis; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Repositioning; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Insulysin; Isoindoles; Molecular Structure; Organoselenium Compounds; Structure-Activity Relationship | 2019 |
The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Analgesics, Non-Narcotic; Animals; Anti-Ulcer Agents; Carbachol; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gastric Acid; Gastric Fistula; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Histamine; Hydrogen-Ion Concentration; Imidazoles; Lansoprazole; Male; Microsomes; Omeprazole; Proton Pump Inhibitors; Pyridines; Stomach; Tetragastrin; Time Factors | 1999 |
Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biological Transport; Cell Line; Humans; Imidazoles; Immunoblotting; Inhibitory Concentration 50; Lansoprazole; Metformin; Omeprazole; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Protein Binding; Proton Pump Inhibitors; Rabeprazole | 2011 |
Pantoprazole, a proton-pump inhibitor, impairs human sperm motility and capacitation in vitro.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Fertilization; Humans; Lansoprazole; Male; Membrane Potentials; Middle Aged; Omeprazole; Pantoprazole; Phosphorylation; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Semen Analysis; Sperm Capacitation; Sperm Maturation; Sperm Motility; Spermatozoa; Young Adult | 2020 |